

REMARKS


Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a Second Substitute Sequence Listing to be inserted into the specification as indicated above. Also submitted herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a disk copy of the Second Substitute Sequence Listing. The disk copy of the Second Substitute Sequence Listing, file "2003-07-17 2121-0140P.st25.txt", is identical to the paper copy, except that it lacks formatting.

Upon review of the Sequence Listing of October 4, 1999, Applicants noted that there was a typographical error in SEQ ID NO:58, which lists the sequence of Figure 10, i.e. the amino acid sequence encoded by the first exon of the nucleotide sequence of SEQ ID NO:22. Specifically, the terminal Gln residue was missing from SEQ ID NO:58. The identification and appropriate correction of the error in SEQ ID NO:58 is evident from both Figure 10 and SEQ ID NO:22. As such, correction of the Sequence Listing is not believed to in any way raise an issue of new matter.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Marc S. Weiner, #32,181
MaryAnne Armstrong, Ph.D., #40,069

MSW/MAA/LPS
2121-0140P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000